Neurol. praxi. 2011;12(6):422-425

News in the treatment of diabetic neuropathy

MUDr.Dana Halbichová
Neurologické oddělení, Dopravní zdravotnictví, Praha

Diabetes mellitus and the treatment of associated complications is a great problem oll over the world. Modern medicine offeres a wide

range of therapeutical possibilities. There are some new drugs in clinical praxis, some are not registrated in Czech republic or their indication

is out off label. Non- pharmaceutical methods can be used as alternative treatment of diabetic neuropathy.

Keywords: diabetic neuropathy, new painkillers, non-pharmacological methods

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Halbichová D. News in the treatment of diabetic neuropathy. Neurol. praxi. 2011;12(6):422-425.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Attal N. EFNS guidelines on the pharmacological treatment of neuropatic pain. 2010 revision. Eur J Neurol 2010; 17: 1113-23. Go to original source... Go to PubMed...
    2. Backonja M. Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002; 5: 14-17. Go to original source... Go to PubMed...
    3. Baconja M, Ravaz A, Veves A. Painful Diabetic Neuropathy: Epidemiology, Natural History, Early Diagnosis, and Treatment Options, Pain Medicine 2008; 9: 660-672. Go to original source... Go to PubMed...
    4. Bartoušek J. Diabetická polyneuropatie v ambulanci praktického lékaře, diabetologa a neurologa - současné možnosti diagnostiky a léčby. Neurol. praxi 2001; 1: 9-10.
    5. Buonocore G, Perrone S, Tataranno ML. Oxygen toxicity: Chemistry and biology of reactive oxygen species. Semin Fetal Neonatal Med. 2010; 15(4): 186-190. Go to original source... Go to PubMed...
    6. Cameron NE, Cotter MA. Role of linolenic acid in diabetic polyneuropathy. In Dyck PL, Thomas PK. Diabetic Neuropathy. Philadelphia: WB Saunders 1999: 359-367.
    7. Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni. Sulodexide in the treatment of intermittent claudication Results of a randomized, doubleblind, multi centre, placebocontrolled study. European Heart Journal 2002; 23: 1057-1065. Go to original source... Go to PubMed...
    8. Goss JR, Goins WF, Lacomis D, Mata M, Gloriolo JC, Fink DJ. Herpes Simplex- Mediated Gene Transfer of Nerve Growth Factor Protects Against Peripheral Neuropathy in Streptozotocin-Induced Diabetes in the Mouse, Diabetes 2002; 51(7): 2227-2232. Go to original source... Go to PubMed...
    9. Herdegen T. Pharmakologie und Toxikologie. Kurzlehrbuch. Thieme, Stuttgart - New York, 1. Auflage 2008: 287. Go to original source...
    10. Hounsom L, Horrobin DF, Tritschler H, Corder R, Tomlinson DR. A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropaty. Diabetologia 1998; 41(7): 839-843. Go to original source... Go to PubMed...
    11. Jasiński DR, Griffith JD, Pevninck J. Nefopam, morphine and d-amphetamin in man: subjective behavorial and Physiologie effects. Pharmacologist 19, 230, abst. Nr. 1977: 580.
    12. Johansson BL, Borg K, Fernqvist E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus, Diabetic medicine 2000; 17: 181-189. Go to original source... Go to PubMed...
    13. Karen I, Kvapil M, Býma S. Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře 2005.
    14. Kršiak M, Doležal T, Lejčko J. Neopioidní analgetika. Bolest. Praha Tigis; 2006; 111-113.
    15. Kvapil M. Zkušenosti z klinických zkoušek, ,Mikrocirkulace", Sympozium Fyzikální léčba metodou diencefalické modulace. 4/10.
    16. Macdonald RL, Greenfield LJ. Mechanism of action of new antiepileptic drugs. Curr Opin Neurol 1997; 10: 121-128. Go to original source... Go to PubMed...
    17. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996; 37; 6: 4-11. Go to original source... Go to PubMed...
    18. Musil R, Šmahelová A, Zadák Z, Sobotka L. Použití mesodiencefalické modulace k zmírnění projevů diabetické polyneuropatie. Praktický Lékař 2007; 11: 664-667.
    19. Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, Naruse K, Kasuya Y, Mizubayashi R, Miwa K, Yasuda Y, Kamiva H, Ienaga K, Sakakibara F, Koh N, Hotta N. A proteinkinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats.Diabetes 1999; 48: 2090-2095. Go to original source... Go to PubMed...
    20. Obšil T, Pavlíček Z. Glykace proteinů a fosfolipidů: Maillardova reakce in vivo. Chemické listy 1997; 91: 558-569.
    21. Polach L. Antidepresiva-stručný přehled. In Antidepresiva-stručný přehled [online]. [s.l.] : [s.n.], 2009 [cit. 2009.08.12]. Dostupné z WWW: <www.lpolach.cz/2009/08/antidepresiva-strucny-prehled/>.
    22. Stocchi F. Die Ergebnisse der ersten Phase-III-Studie mit Safinamid als Begleittherapie zu Dopaminagonisten (DA) bei Parkinson- Frühstadium beim 59. Jahreskongress der Amerikanischen Akademie für Neurologie in American Academy of Neurology Boston 2007.
    23. Škrha J. Patofyziologie a patogeneze diabetické polyneuropatie. Diabetes a diabetická onemocnění 2004; (Suppl): 529-534.
    24. Tesfaye S. Diabetic Peripheral Neuropathy in PlaceboAdministered Patiens From Two Year Clinical trials. Diabetes Care 2007; 10: 2626-2632. Go to original source... Go to PubMed...
    25. Troels SJ. Anticonvulsants in neuropathic pain: rationale and clinical evidence. European Journal of Pain 2002; 6: 61-68. Go to original source... Go to PubMed...
    26. Veselý M. Aktivní kyslík O3-Ozon. Praha; Tisk Znamenaný 2000: 14-29.
    27. Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Bastyr EJ. Treatment of symptomatic diabetic peripheral neuropaty with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo controlled, double-blind clinical trial. ClinTher 2005; 27(8): 1164-1180. Go to original source...
    28. Virally M, Blické JF, Girad J. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives; Diabetes & Metabolism 2007; 33: 231-244. Go to original source... Go to PubMed...
    29. Vondrová H. Léčba diabetické polyneuropatie. Neurol. praxi 2008; 4: 228-233.
    30. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral Treatment With ?-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy; Diabetes care; 2006; 29: 2365-2370. Go to original source... Go to PubMed...
    31. Wirktstoffe Flupirtin. Medicine und Gesundheit [online]. 19.2.2009, 3, [cit. 2011-06-13]. Dostupný z WWW: <http://medikamente.onmeda.de/Wirkstoffe/Flupirtin.html>.
    32. Život s diabetem [online]. 2009 [cit. 2011-06-18]. Cukrovka v číslech. Dostupné z WWW: <http://www.zivotsdiabetem.cz/co-je-diabetes/podrobnosti-o-nemoci/124-cukrovka-v-cislech>.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.